We report three patients with relapsed ovarian cancer who developed femoral head necrosis requiring endoprosthetic hip surgery 16-35 months after high-dose chemotherapy (HDC) with treosulfan (47 and 56 g/m 2 body-surface area (BSA)) given as 3-25 h infusions and followed by autologous peripheral blood stem cell (PBSC) transplantation. One woman received two courses of single agent treosulfan while the other two patients received one course of high-dose treosulfan either preceded or followed by high-dose carboplatin, etoposide and cyclophosphamide. A total of 30 women with ovarian cancer were treated with HDC at our unit and 21 of them received treosulfancontaining regimens. Femoral head necrosis was not observed in patients either receiving conditioning regimens without treosulfan (n ¼ 9) or when the total treosulfan dose was given over 3 consecutive days (n ¼ 3) or in patients with a diagnosis other than ovarian cancer and treated with high-dose treosulfan (n ¼ 10). We conclude that women with relapsed ovarian cancer receiving HDC with excessive single-dose treosulfan might be at an increased risk of developing bone necrosis.
Loss of bone mineral density (BMD) is a known side effect of high dose chemotherapy (HDC) and stem cell transplantation and has increasing importance in long-term survivors of such intensive treatment regimens. It is mainly observed after allogeneic stem cell transplantation and there is a correlation between the cumulative dose and number of days of glucocorticoid therapy and the number of days of cyclosporine or tacrolimus and the loss of BMD, while total body irradiation, diagnosis or donor type have no influence. 1 Ebeling et al 2 reported a loss of 11.7% femoral neck BMD post-allo-bone marrow transplantation (BMT) as compared with a nonsignificant decrease of 1.1% post-auto BMT. In addition, the same group observed an avascular necrosis of the femoral head in four, and vertebral and rib fractures in another one of 116 patients surviving longer than 6 months post-allo-BMT. All skeletal events occurred a median of 19 months post-HDC and were observed only in patients receiving allo-BMT, while no such complications were reported after autologous transplantation. In addition, low testosterone and estrogen serum levels and secondary hyperparathyroidism because of low serum calcium 3 and cytoreductive chemotherapy prior to transplantation 4 are further risk factors. Patients undergoing bilateral oophorectomy may suffer a loss of trabecular bone as great as 20% during the first 18 months after surgery. 5 While loss of BMD is not uncommon, the occurrence of avascular bone necrosis in patients with ovarian cancer has been reported only sporadically. 6 HDC with treosulfan, a prodrug of a bifunctional alkylating cytotoxic agent has been used in a clinical phase I dose escalation and pharmacokinetic study with autologous peripheral blood stem cell (PBSC) transplantation in patients with ovarian cancer (n ¼ 20), lymphoma (n ¼ 4), myeloma, yolk sac tumor, breast cancer and sarcoma (n ¼ 1 each). Ten other patients diagnosed with ovarian cancer received treosulfan-containing regimens outside of this phase I study. Pharmacokinetic data of 16 of these HDC courses with treosulfan have been published recently. 7 Three of the patients with ovarian cancer treated at our clinic developed femoral head necrosis, suggesting that high-dose treosulfan or one of its metabolites including methane sulfonic acid that is released during the formation of the monoepoxy intermediate and its further metabolism to l-(+)-diepoxybutane, respectively, could have contributed to this complication. The clinical course of these patients is described and compared with pharmacokinetic data.
Patients
Patient 1, M.D., was diagnosed with adeno carcinoma of the left ovary in April 1996 at the age of 49 years. She underwent bilateral oophorectomy, hysterectomy, sigmoid colon resection and removal of two small-bowel metastases. From April to September 1996 she received six courses of cyclophosphamide and cisplatin, but residual disease was found on second-look surgery and three additional courses of chemotherapy with cyclophosphamide and cisplatin were added. Third-look surgery in May 1997 showed no evidence of disease. In November 1997 raising Ca 12-5 serum levels and splenic, lymphonodular and mesenterial recurrences were found, and two courses of cisplatin and paclitaxel were started. Cyclophosphamide (3 g/m 2 ) for PBSC mobilization was given in January 1998 followed by two further courses of cisplatin and paclitaxel. In March 1998 the first HDC with the CEC regimen ( Table 1 ) was given and 3.2Â10 6 CD34+ cells/kg body weight (bw) were transfused, resulting in complete remission. The second HDC with 56 g/m 2 treosulfan given as a 4-h-infusion followed in April 1998, and 6.4Â10 6 CD34+ cells/kg bw were infused. In March 1999 splenic recurrence was diagnosed and subsequent sequential chemotherapeutic regimens were applied including 5-fluorouracil and folinic acid (FU/FA) with or without mitomycin C, gemcitabine (GEM), epirubicin and tamoxifen and oral etoposide with or without carboplatin. In October 1999 the course was complicated by a local recurrence in the left side of the pelvis, small-bowel obstruction and ischemic colitis necessitating surgery further complicated by renal failure, respiratory insufficiency and bioccipital insults. However, she recovered fully but suffered from increasing bilateral hip pain. In September 2000 she underwent endoprosthetic hip replacement surgery of the right (Figure 1 ), and in July 2001 of the left hip. In between and after the second surgery she was treated again for persistent ovarian cancer with additional courses of etoposide and carboplatin, oral cyclophosphamide, CPT-11, GEM, FU/FA and weekly paclitaxel. At the present time she is in good clinical condition (WHO I) and no further skeletal complications have occurred to date.
Patient 2, V.B., underwent bilateral oophorectomy, hysterectomy and omental resection in April 1994 for grade 2-3 ovarian cancer stage FIGO III. She received five courses of cisplatin and cyclophosphamide followed by paclitaxel which was complicated by allergic shock after the second infusion. In October 1996 she underwent surgery for perirectal recurrence and in January 1998 a small-bowel resection was carried out after a pelvic relapse. In April 1998 she received cyclophosphamide (3 g/m 2 ) for PBSC mobilization, and two courses of high-dose treosulfan (56 g/m 2 given as a 3-and 4-h infusion) with PBSC support (1.7 and 2.7Â10 6 CD34+ cells/kg bw, respectively) were given in May and July 1998. Another pelvic relapse with vaginal invasion occurred in August 1999 for which she was irradiated. The total dose was 50.4 Gy and included the medial part of the right femoral head (local dose o50 Gy). Increasing serological tumor markers and lymphonodular disease were found 5 months later and treatment with FU/FA and cisplatin was initiated. In ).
Treosulfan and osteonecrosis P Bojko et al cells/kg bw) for persisting thrombocytopenia. Upon completion of HDC she was complaining of pain in her shoulders, hips and knees and conventional radiology showed irregularity of the right femoral head consistent with avascular necrosis (Figure 2 ). Endoprosthetic hip replacement surgery was carried out in April 2001 and necrosis of the right femoral head was confirmed historically. Further treatment with GEM was given for peritoneal progress and elevated serological tumor markers. Patient 3, I.P., had a highly differentiated cystadenocarcinoma FIGO III of the left ovary treated with bilateral adnexectomy, hysterectomy and lymphonodular resection in January 1995 followed by six courses of adjuvant chemotherapy with cisplatin and cyclophosphamide. From October to December 1998 she received paclitaxel and cisplatin (Â3) followed by two courses of cyclophosphamide for PBSC mobilization because of peritoneal dissemination accompanied by serological tumor marker elevation. HDC with treosulfan (47 g/m 2 over 25 h) was started in January 1999. A second course of HDC with the CEC regimen ( Table 1 ) was added in February 1999. 2.9 and 6.8Â10 6 CD34+ cells/kg bw were transfused after the first and second HDC, respectively. In August 1999 her serum Ca 12-5 was rapidly increasing and she was treated with FU/FA plus vinorelbine until December 1999. From this time she complained of pain in both hipjoints and MRI showed changes consistent with bilateral femoral head necrosis (Figure 3 ). Endoprosthetic hip surgery of the right side was performed in April 2000. Surgery of the left hip has been recommended after recovery but has not been performed to date. Chemotherapy with FU/FA and vinorelbine was resumed in June 2000 and was switched to GEM in July because of increasing Ca 12-5 serum levels. Topotecan was started in January 2001 when pleural effusions occurred, and finally carboplatin and paclitaxel were given upon disease progression in April 2001. The last treatment was given by a community oncologist and the patient was lost to follow-up in July 2001.
Discussion
Bone necrosis is a rare complication after HDC and autologous stem cell transplantation. 2 The beginning of the symptoms relating to bone necrosis in our patients was between 5 (patient 3, I.P.) and 10 months (patient 2, V.B.) upon completion of HDC with treosulfan. For patient 1 (M.D.) the exact beginning could not be recalled. Hip surgery was carried out between 16 and 35 months (mean 26 months) after HDC with treosulfan (Table 1) . We have recently conducted a phase I dose escalation and pharmacokinetic study of HDC treosulfan with autologous PBSC support. Treosulfan doses ranged from 16 to 56 g/m 2 BSA applied either as 2-4 h (29 courses in 24 patients) or 24-25 h-infusion (seven courses in six patients), and the results of patients receiving a 2-h infusion have been published recently. 7 The three patients reported here respectively, excluding the possible explanation that excessive peak serum levels of treosulfan may be responsible for the occurrence of bone necrosis. Figure 4 shows typical plasma concentration curves for treosulfan after different applications (2-h infusion, 24-h infusion, split doseinfusion over 2-h for 3 days). The highest AUC, however, was measured in patient 1 (M.D., 8360 mg/mlÂh, range for all other patients 1390 to 7710 mg/mlÂh after 2-4 h-infusion and 2450 to 4930 mg/mlÂh during 24 h-infusion), while the corresponding values for patient 2 (V.B.) and 3 (I.P.) were 5600 (HDC #1) and 5610 (HDC #2) and 4720 mg/mlÂh, respectively. Figure 5a shows the AUC vs. dose-level of 35 high-dose chemotherapies with treosulfan. The values for the three patients reported here fall into the right upper end of the plot, suggesting at least some correlation between AUC and the observed side effects. Four therapies conducted with split-dose treosulfan (ie daily infusion for 3 consecutive days with total doses of up to 45 g/m 2 ) resulted in similar cumulative AUC-values after three consecutive days. However, no osteonecrosis occurred in the corresponding patients. This is in accordance with results published by Wagner et al 8 or Baynes et al. 9 Reichle and co-workers have now conducted a total of 109 autologous transplants after high-dose therapy with treosulfan, carboplatin and etoposide in patients with lymphoma and ovarian cancer. Femoral head necrosis was observed in one patient only, who received a combination of autologous and allogeneic transplantation and required steroid treatment for severe graft-versus-host disease, while no such complication was seen after autologous transplantation with cumulative absolute treosulfan doses of up to 84 g/m 2 (Reichle et al, personal communication). Together, these data indicate that the time schedule of infusion of excessive doses of treosulfan might be an important factor. For comparison, Figure 5b shows the plot of the applied dose-level and c max .
Another possible explanation for the occurrence of osteonecrosis could be the release of methane sulfonic acid (MSA) during the formation of a monoepoxide and l-(+)-diepoxybutane. A total of 2 mol MSA are released for each mole of treosulfan during transformation into the active metabolites. To our knowledge, the importance of increased MSA serum levels has not been studied before and we found no literature about osteonecrosis and MSA. However, this hypothesis would need confirmation in animal models, for example.
The fact that no skeletal events were observed in patients with diagnoses other than ovarian cancer is indicative that prior oophorectomy with subsequent endocrine deprivation might be an additional trigger for the induction of bone necrosis. The application of steroids as a further risk factor must be considered, but it is part of most high-dose or cisplatin-containing chemotherapy regimens and given to many patients without subsequent bone necrosis. Patient 2 received pelvic irradiation including the medial part of the right femoral head. However, according to the treating radiotherapist, radiation field and local dose should not be causative for femoral head necrosis, but additional triggering cannot be ruled out completely.
Patients who are scheduled for HDC and stem cell transplantation usually present with advanced disease and the main focus is induction of remission of their underlying malignancy and to keeping them alive. Although the risk of bone necrosis is low, this complication should be kept in mind especially in patients treated with high-dose treosulfan and allogeneic stem cell transplantation followed by steroids and other immunosuppressants. Modified schedules such as splitting the treosulfan dose seem to be an easy way for safe use of this otherwise well-tolerated and effective drug.
